BEVERLY HARRIS: Open Payments
NPI 1255585485 · GROTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,856 in 59 payments from 21 companies in 2025. Trend: 2023 $3,381 · 2024 $3,521 · 2025 $1,856
Food & beverage: $1,787Education: $69
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $315 |
| Janssen Biotech, Inc. | 6 | $250 |
| UCB, Inc. | 7 | $222 |
| AstraZeneca Pharmaceuticals LP | 7 | $176 |
| Madrigal Pharmaceuticals | 1 | $140 |
| ACADIA Pharmaceuticals Inc | 1 | $101 |
| Sandoz Inc. | 3 | $81 |
| Lilly USA, LLC | 3 | $73 |
| Calliditas Therapeutics US Inc. | 1 | $71 |
| Amgen Inc. | 3 | $63 |
Products named: TREMFYA, Bimzelx, BENLYSTA, REZDIFFRA, BLUJEPA, NUPLAZID, FARXIGA, MOUNJARO.
Industry payments across MA — which companies pay providers there.
